Is my portfolio
One Report to Answer all your Questions!
Natco Pharma Ltd.
BSE: 524816 | NSE: NATCOPHARM
Small Cap | Pharmaceuticals & Drugs
927.15
3.50 (0.38%) NATCO Pharma informs about disclosure
Date: 09-11-2022NATCO Pharma has informed that it enclosed the disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding ‘NATCO Announces Launch of First Generic Version of Pomalyst® (Pomalidomide) Capsules in the Australian Market’.
The above information is a part of company’s filings submitted to BSE.